Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2010
08/12/2010US20100204213 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
08/12/2010US20100204212 Fused heterocyclic compounds useful as kinase modulators
08/12/2010US20100204208 Protein kinase c inhibitors and uses thereof
08/12/2010US20100204205 Tolerability of mirtazapine and a second active agent by using them in combination
08/12/2010US20100204202 Drug for alleviating motor complications or psychiatric symptoms of parkinson's disease
08/12/2010US20100204199 Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors
08/12/2010US20100204192 Agents, compositions and methods for enhancing neurological function
08/12/2010US20100204191 Function-Selective Vitamin D Receptor Agonist
08/12/2010US20100204190 New combinations
08/12/2010US20100204184 Phosphonates useful as modulators of T-gamma-9-delta-2 activity
08/12/2010US20100204183 Substituted Phosphonates and Their Use In Decreasing Amyloid Aggregates
08/12/2010US20100204182 Ectonucleotidase inhibitors
08/12/2010US20100204179 Resveratrol complex and process for the preperation
08/12/2010US20100204178 Novel parenteral carbamazepine formulation
08/12/2010US20100204162 Substrate reduction therapy
08/12/2010US20100204160 Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof
08/12/2010US20100204157 Use of a peptide as a therapeutic agent
08/12/2010US20100204155 Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
08/12/2010US20100204154 Use of the peptide rfmwmr as a therapeutic agent
08/12/2010US20100204153 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
08/12/2010US20100204151 Use of a peptide as a therapeutic agent
08/12/2010US20100204150 Use of a peptide as a therapeutic agent
08/12/2010US20100204149 Use of octreotide as a therapeutic agent
08/12/2010US20100204148 (d-leu7 ) -histrelin as a therapeutic agent
08/12/2010US20100204145 Use of a peptide as a therapeutic agent
08/12/2010US20100204144 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
08/12/2010US20100204143 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
08/12/2010US20100204142 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
08/12/2010US20100204141 Use of bpp-b as a therapeutic agent
08/12/2010US20100204140 Use of a peptide as a therapeutic agent
08/12/2010US20100204139 Use of gonadorelin as a therapeutic agent
08/12/2010US20100204138 Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
08/12/2010US20100204136 Use of a peptide as a therapeutic agent
08/12/2010US20100204135 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
08/12/2010US20100204134 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent
08/12/2010US20100204132 THERAPEUTIC USES OF PEPTIDES YSAYPDSVPMMS and WMNSTGFTKVCGAPPC
08/12/2010US20100204130 Use of human neuropeptide as a therapeutic agent
08/12/2010US20100204127 Use of a botulinum neurotoxin to alleviate various disorders
08/12/2010US20100204124 Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
08/12/2010US20100204123 Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
08/12/2010US20100204118 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents
08/12/2010US20100204113 Use of stresscopin-related peptide as a therapeutic agent
08/12/2010US20100204112 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
08/12/2010US20100204111 Astressin and beta- endorphin for use as therapeutic agents
08/12/2010US20100204110 Use of a peptide as a therapeutic agent
08/12/2010US20100204109 Use of c-type natriuretic peptide, alone or in combination with neuropeptide af, as a therapeutic agent
08/12/2010US20100204108 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents
08/12/2010US20100204107 Use of urodilatin as a therapeutic agent
08/12/2010US20100204106 Use of GIP for the Treatment of Disorders Associated with Dysfunctional Synaptic Transmission
08/12/2010US20100204100 Biological agents active in central nervous system
08/12/2010US20100204090 Use of a peptide as a therapeutic agent
08/12/2010US20100204089 Phosphorylated pyrone analogs and methods
08/12/2010US20100204085 Structure-based design of peptide inhibitors of amyloid fibrillation
08/12/2010US20100203628 Novel modified galectin 9 proteins and use thereof
08/12/2010US20100203156 Xenon as a treatment for hemoglobinopathy
08/12/2010US20100203151 Microspheres having core/shell structure
08/12/2010US20100203128 Bupropion hydrobromide and therapeutic applications
08/12/2010US20100203123 Methods for improving cognitive function and decreasing heart rate
08/12/2010US20100203104 Delivery system for risperidone
08/12/2010US20100203090 Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine
08/12/2010US20100203083 Mutated structural protein of a parvovirus
08/12/2010US20100203044 Dr6 antagonists and uses thereof in treating neurological disorders
08/12/2010US20100203022 Methods and compositions for delivering therapeutic agents to the central nervous system
08/12/2010US20100203017 Cladribine Regimen for Treating Multiple Sclerosis
08/12/2010US20100203007 Novel benzodiazepine derivatives
08/12/2010US20100202968 Method of Providing Disease-Specific Binding Molecules and Targets
08/12/2010DE202010004062U1 Unterstützung bei Zappelphilipp-Syndrom Assistance with hyperactivity syndrome
08/12/2010CA2751638A1 Medicinal use of 5-benzylaminosalicylic acid derivative or its salt
08/12/2010CA2751536A1 Indoline derivatives
08/12/2010CA2751535A1 Substituted spiro-amides as b1r modulators
08/12/2010CA2751531A1 Vector(s) containing an inducible gene encoding a cdk4/cdk6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of thecell cycle
08/12/2010CA2751481A1 Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
08/12/2010CA2751402A1 Substituted indole compounds as bradykinin receptor 1 modulators
08/12/2010CA2750714A1 Dihydroquinolinone derivatives
08/12/2010CA2749856A1 Isoxazole-3-carboxamide derivatives
08/12/2010CA2748862A1 Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
08/11/2010EP2216409A1 Albumin fusion proteins
08/11/2010EP2216047A1 Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient
08/11/2010EP2216040A1 Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression
08/11/2010EP2216039A1 Pharmaceutical compositions for treating anxiety
08/11/2010EP2216038A1 Pharmaceutical compositions for treating depression and anxiety
08/11/2010EP2215114A1 Chimeric relaxin polypeptides comprising an a and b chain derived from different relaxin family peptides
08/11/2010EP2215094A1 N-containing heterocyclic compounds
08/11/2010EP2215090A1 Purine derivatives useful as pi3 kinase inhibitors
08/11/2010EP2215073A1 Modulation of sleep with nr2b receptor antagonists
08/11/2010EP2215072A2 Polymorphic form of rotigotine
08/11/2010EP2215058A1 Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
08/11/2010EP2215052A1 Desferrioxamine conjugates, derivatives and analogues
08/11/2010EP2215044A1 Biphenyl carboxylic acids and derivatives thereof
08/11/2010EP2215043A1 Carbon linked modulators of y-secretase
08/11/2010EP2214714A1 A new class of therapeutics that enhance small molecule diffusion
08/11/2010EP2214713A1 Memantine protects inflammation-related degeneration of dopamine neurons through inhibition of over-activated microglia and release of neurotrophic factors from astroglia
08/11/2010EP2214698A2 Use of compounds activating sirt-3 for mimicking exercise
08/11/2010EP2214681A1 Novel nutraceutical compositions containing stevia extract or stevia extract constituents and uses thereof
08/11/2010EP2214672A2 Combination analgesic employing opioid and neutral antagonist
08/11/2010EP2214666A1 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
08/11/2010EP2214657A1 Compounds for treating demyelination conditions
08/11/2010EP2214649A1 Compositions for treating parkinson's disease
08/11/2010EP2214518A1 Metabolic enhancement therapy
08/11/2010EP2214488A1 Compositions and methods for treating parkinson's disease and related disorders
1 ... 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 ... 1833